Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Autoimmune disease

Autoimmune disease; multiple sclerosis (MS)

Chemokine CXC motif ligand 11 (CXCL11)

Mouse studies suggest low doses of CXCL11 could be useful for treating autoimmune conditions such as MS. In a mouse model of experimental autoimmune encephalomyelitis (EAE), a Cxcl11-Ig fusion molecule induced remission and prevented relapse, whereas a Cxcl10 (Ip-10)-Ig fusion molecule, control IgG or saline did not. In an EAE mouse model with Cxcl11 deficiency, treatment with low doses of Cxcl11 suppressed development of EAE, whereas saline treatment did not. Next steps could include evaluating CXCL11-based therapies in additional models of autoimmune disease.

SciBX 7(18); doi:10.1038/scibx.2014.514
Published online May 8, 2014

Patented; available for licensing from Technion-Israel Institute of Technology
Contact: Orit Shaked, Technion-Israel Institute of Technology, Haifa, Israel
e-mail:

oshaked@tx.technion.ac.il

Zohar, Y. et al. J. Clin. Invest.;
published online April 8, 2014;
doi:10.1172/JCI71951
Contact: Nathan Karin, Technion-Israel Institute of Technology,
Haifa, Israel
e-mail:

nkarin10@gmail.com